8-K Announcements
6Material company update
Apr 9, 2026·SEC
Material company update
Apr 3, 2026·SEC
Material company update
Apr 2, 2026·SEC
FibroBiologics, Inc. Common Stock(FBLG)Earnings, Financials & Key Ratios
FBLG•NASDAQ
$1.24
$3M mkt cap·Price updated May 7, 2026
AboutFibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.Show more
- Revenue$0
- EBITDA-$16M-20.2%
- Net Income-$19M-67.1%
- EPS (Diluted)-8.40-23.5%
- ROE-419.44%+25.1%
- ROIC-839.45%
- Debt/Equity0.39-89.9%
- Interest Coverage-90.40+83.8%
FBLG Key Insights
FibroBiologics, Inc. Common Stock (FBLG) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.4x book value
✗Weaknesses
- ✗Profits declining 74.0% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 1 (bottom 1%)
- ✗Shares diluted 35.8% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
FBLG Price & Volume
FibroBiologics, Inc. Common Stock (FBLG) stock price & volume — 10-year historical chart
Loading chart...
FBLG Growth Metrics
FibroBiologics, Inc. Common Stock (FBLG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-67.06%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-29.46%
Return on Capital
10 Years-1516.14%
5 Years-1516.14%
3 Years-1763.31%
Last Year-287.57%
FBLG Recent Earnings
FibroBiologics, Inc. Common Stock (FBLG) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (43%)
Q1 2026Latest
Feb 24, 2026EPS
$0.98
Est $1.44
+31.9%
Revenue
—
Q4 2025
Oct 31, 2025EPS
$0.13
Est $0.10
-30.0%
Revenue
—
Q3 2025
Jul 31, 2025EPS
$0.12
Est $0.11
-9.1%
Revenue
—
Q2 2025
Mar 31, 2025EPS
$0.09
Est $0.10
+10.0%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 24, 2026 | $0.98vs $1.44+31.9% | — |
| Q4 2025 | Oct 31, 2025 | $0.13vs $0.10-30.0% | — |
| Q3 2025 | Jul 31, 2025 | $0.12vs $0.11-9.1% | — |
| Q2 2025 | Mar 31, 2025 | $0.09vs $0.10+10.0% | — |
Based on last 12 quarters of dataView full earnings history →
FBLG Peer Comparison
FibroBiologics, Inc. Common Stock (FBLG) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MESO | 1.91B | 14.80 | -17.62 | 191.39% | -5.94% | -17.1% | 0.21 | |
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 MDXG | 548.21M | 3.69 | 11.53 | 19.99% | 7.88% | 12.86% | 0.09 | |
 RGEN | 7.13B | 126.43 | 147.01 | 16.36% | 6.73% | 2.46% | 0.33 | |
 FATE | 280.32M | 2.43 | -2.11 | -51.24% | -20.51% | -65.79% | 0.38 | |
 CELC | 5.66B | 130.71 | -46.19 | -179% | 0.85 | |||
 VCEL | 1.79B | 35.13 | 109.78 | 16.45% | 7.35% | 6.41% | 0.28 | |
 RCUS | 2.5B | 24.80 | -7.54 | -4.26% | -156.36% | -68.97% | 0.16 |
Compare FBLG vs Peers
FibroBiologics, Inc. Common Stock (FBLG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FBLG Income Statement
FibroBiologics, Inc. Common Stock (FBLG) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 832K |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -832K▲ 0% |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - |
| Operating Expenses | 1.17M | 1.58M | 4.47M | 8.89M | 13.74M | 15.82M |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 500K | 1.06M | 3.32M | 6.52M | 9.23M | 9.24M |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 669K | 521K | 1.15M | 2.37M | 4.5M | 7.41M |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -832K |
| Operating Income | -1.17M▲ 0% | -1.58M▼ 35.0% | -4.47M▼ 183.1% | -8.89M▼ 99.0% | -13.74M▼ 54.5% | -16.65M▼ 21.2% |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | - | -34.99% | -183.08% | -98.99% | -54.54% | -21.2% |
| EBITDA | 0 | -1.58M | -4.37M | -8.45M | -13.16M | -15.82M |
| EBITDA Margin % | - | - | - | - | - | - |
| EBITDA Growth % | - | - | -177.12% | -93.28% | -55.75% | -20.15% |
| D&A (Non-Cash Add-back) | 1.17M | 0 | 94K | 437K | 573K | 832K |
| EBIT | -1.17M | -1.58M | -4.47M | -16.34M | -11.14M | -18.44M |
| Net Interest Income | 0 | -4K | -654K | -147K | 231K | 43K |
| Interest Income | 0 | 0 | 0 | 0 | 251K | 247K |
| Interest Expense | 0 | 4K | 654K | 147K | 20K | 204K |
| Other Income/Expense | 0 | -4K | -654K | -7.6M | 2.58M | -2M |
| Pretax Income | -1.17M▲ 0% | -1.58M▼ 35.3% | -5.12M▼ 223.7% | -16.48M▼ 221.9% | -11.16M▲ 32.3% | -18.65M▼ 67.1% |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -1.17M▲ 0% | -1.58M▼ 35.3% | -5.12M▼ 223.7% | -16.48M▼ 221.9% | -11.16M▲ 32.3% | -18.65M▼ 67.1% |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | - | -35.33% | -223.7% | -221.91% | 32.3% | -67.06% |
| Net Income (Continuing) | -1.17M | -1.58M | -5.12M | -16.48M | -11.16M | -18.65M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.72▲ 0% | -0.97▼ 35.3% | -3.20▼ 228.5% | -11.80▼ 268.8% | -6.80▲ 42.4% | -8.40▼ 23.5% |
| EPS Growth % | - | -35.28% | -228.54% | -268.75% | 42.37% | -23.53% |
| EPS (Basic) | -0.72 | -0.97 | -3.20 | -11.80 | -6.80 | -8.40 |
| Diluted Shares Outstanding | 1.62M | 1.62M | 1.62M | 1.62M | 1.64M | 2.23M |
| Basic Shares Outstanding | 1.62M | 1.62M | 1.62M | 1.62M | 1.64M | 2.23M |
| Dividend Payout Ratio | - | - | - | - | - | - |
FBLG Balance Sheet
FibroBiologics, Inc. Common Stock (FBLG) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
| Total Current Assets | 0 | 468K | 2.63M | 9.21M | 14.23M | 6.35M |
| Cash & Short-Term Investments | 0 | 407K | 2.27M | 9.16M | 13.98M | 4.89M |
| Cash Only | 0 | 407K | 2.27M | 9.16M | 13.98M | 4.89M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 300K | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 0 | 24K | 30K | 16K | 18K | 1.46M |
| Total Non-Current Assets | 0 | 0 | 2.2M | 2.61M | 2.22M | 3.27M |
| Property, Plant & Equipment | 0 | 0 | 2.2M | 2.61M | 2.22M | 3.22M |
| Fixed Asset Turnover | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 48K |
| Total Assets | 0▲ 0% | 468K▲ 0% | 4.82M▲ 930.8% | 11.82M▲ 145.0% | 16.45M▲ 39.1% | 9.62M▼ 41.5% |
| Asset Turnover | - | - | - | - | - | - |
| Asset Growth % | - | - | 930.77% | 145.05% | 39.12% | -41.51% |
| Total Current Liabilities | 0 | 1.76M | 7.07M | 9.18M | 12.73M | 1.76M |
| Accounts Payable | 0 | 233K | 493K | 1.44M | 2.7M | 0 |
| Days Payables Outstanding | - | - | - | - | - | - |
| Short-Term Debt | 0 | 1.3M | 5.45M | 0 | 9.17M | 706K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 803K | 7.24M | 460K | 1.05M |
| Current Ratio | - | 0.27x | 0.37x | 1.00x | 1.12x | 3.61x |
| Quick Ratio | - | 0.27x | 0.37x | 1.00x | 1.12x | 3.61x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 1.75M | 1.39M | 984K | 1.7M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 1.7M |
| Capital Lease Obligations | 0 | 0 | 1.75M | 1.39M | 984K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 0 | 1.76M | 8.82M | 10.57M | 13.71M | 3.46M |
| Total Debt | 0 | 1.3M | 7.52M | 1.75M | 10.55M | 2.41M |
| Net Debt | 0 | 893K | 5.26M | -7.42M | -3.43M | -2.48M |
| Debt / Equity | - | - | - | 1.39x | 3.86x | 0.39x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | - | -394.50x | -6.83x | -111.14x | -557.05x | -90.40x |
| Total Equity | 0▲ 0% | -1.29M▲ 0% | -4M▼ 209.8% | 1.25M▲ 131.4% | 2.73M▲ 118.3% | 6.16M▲ 125.1% |
| Equity Growth % | - | - | -209.77% | 131.36% | 118.28% | 125.08% |
| Book Value per Share | - | -0.79 | -2.46 | 0.77 | 1.66 | 2.76 |
| Total Shareholders' Equity | 0 | -1.29M | -4M | 1.25M | 2.73M | 6.16M |
| Common Stock | 1.17M | 0 | 1K | 1K | 0 | 1K |
| Retained Earnings | -1.17M | -2.75M | -7.87M | -24.36M | -35.52M | -54.16M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 1.46M | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
FBLG Cash Flow Statement
FibroBiologics, Inc. Common Stock (FBLG) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
| Cash from Operations | -1.17M | -1.41M | -4.07M | -6.4M | -11.9M | -16.39M |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | - | -20.62% | -188.37% | -57.43% | -85.92% | -37.75% |
| Net Income | -1.17M | -1.58M | -5.12M | -16.48M | -11.16M | -18.65M |
| Depreciation & Amortization | 0 | 0 | 94K | 437K | 573K | 832K |
| Stock-Based Compensation | 0 | 0 | 265K | 1.76M | 2.22M | 2.69M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 0 | 389K | 7.39M | -4.09M | 2.05M |
| Working Capital Changes | 0 | 172K | 307K | 493K | 559K | -3.31M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 525K | 671K | 1.25M | 0 |
| Cash from Investing | 0 | 0 | 0 | -495K | -184K | -262K |
| Capital Expenditures | 0 | 0 | 0 | -495K | -184K | -262K |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 1.17M | 1.82M | 5.92M | 13.79M | 16.91M | 7.57M |
| Debt Issued (Net) | 0 | 1.52M | 3.77M | 300K | 9.4M | 975K |
| Equity Issued (Net) | 0 | 0 | 2.15M | 16.14M | 7.51M | 6.59M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.17M | 292K | 0 | -2.65M | 0 | 0 |
| Net Change in Cash | 0▲ 0% | 407K▲ 0% | 1.86M▲ 356.8% | 6.9M▲ 271.0% | 4.82M▼ 30.1% | -9.09M▼ 288.5% |
| Free Cash Flow | -1.17M▲ 0% | -1.41M▼ 20.6% | -4.07M▼ 188.4% | -6.9M▼ 69.6% | -12.09M▼ 75.2% | -16.66M▼ 37.8% |
| FCF Margin % | - | - | - | - | - | - |
| FCF Growth % | - | -20.62% | -188.37% | -69.6% | -75.25% | -37.82% |
| FCF per Share | -0.72 | -0.87 | -2.50 | -4.24 | -7.35 | -7.46 |
| FCF Conversion (FCF/Net Income) | 1.00x | 0.89x | 0.79x | 0.39x | 1.07x | 0.88x |
| Interest Paid | 0 | 0 | 0 | 2K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
FBLG Key Ratios
FibroBiologics, Inc. Common Stock (FBLG) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -1315.64% | -559.73% | -419.44% |
| Return on Invested Capital (ROIC) | - | - | -774.62% | - | - | -839.45% |
| Debt / Equity | - | - | - | 1.39x | 3.86x | 0.39x |
| Interest Coverage | - | -394.50x | -6.83x | -111.14x | -557.05x | -90.40x |
| FCF Conversion | 1.00x | 0.89x | 0.79x | 0.39x | 1.07x | 0.88x |
FBLG SEC Filings & Documents
FibroBiologics, Inc. Common Stock (FBLG) SEC filings — annual & quarterly reports (10-K, 10-Q)
FBLG Frequently Asked Questions
FibroBiologics, Inc. Common Stock (FBLG) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
FibroBiologics, Inc. Common Stock (FBLG) grew revenue by 0.0% over the past year. Growth has been modest.
FibroBiologics, Inc. Common Stock (FBLG) reported a net loss of $18.6M for fiscal year 2025.
Dividend & Returns
FibroBiologics, Inc. Common Stock (FBLG) has a return on equity (ROE) of -419.4%. Negative ROE indicates the company is unprofitable.
FibroBiologics, Inc. Common Stock (FBLG) had negative free cash flow of $16.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More FBLG
FibroBiologics, Inc. Common Stock (FBLG) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates